Frontiers in Plant Science,
Journal Year:
2022,
Volume and Issue:
13
Published: Feb. 7, 2022
Artemisinin
is
a
natural
bioactive
sesquiterpene
lactone
containing
an
unusual
endoperoxide
1,
2,
4-trioxane
ring.
It
derived
from
the
herbal
medicinal
plant
Artemisia
annua
and
best
known
for
its
use
in
treatment
of
malaria.
However,
recent
studies
also
indicate
potential
artemisinin
related
compounds,
commonly
referred
to
as
artemisinins,
combating
viral
infections,
inflammation
certain
cancers.
Moreover,
different
modes
action
artemisinins
make
these
compounds
potentially
relevant
challenges
world
faces
COVID-19
pandemic.
Initial
positive
effects
or
spp.
extracts
combat
SARS-CoV-2
infection
symptoms
WHO-supervised
clinical
on
are
now
progress.
implementing
multiple
new
uses
will
require
effective
solutions
boost
production,
either
by
enhancing
synthesis
A.
itself
through
biotechnological
engineering
alternative
biosynthesis
platforms.
Because
this
renewed
interest
derivatives,
here
we
review
action,
application
diseases
including
COVID-19,
future
options
production.
Biomolecules,
Journal Year:
2021,
Volume and Issue:
11(7), P. 993 - 993
Published: July 6, 2021
Severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
is
the
etiological
agent
of
disease
2019
(COVID-19)
pandemic,
which
has
been
a
topic
major
concern
for
global
human
health.
The
challenge
to
restrain
COVID-19
pandemic
further
compounded
by
emergence
several
SARS-CoV-2
variants
viz.
B.1.1.7
(Alpha),
B.1.351
(Beta),
P1
(Gamma)
and
B.1.617.2
(Delta),
show
increased
transmissibility
resistance
towards
vaccines
therapies.
Importantly,
there
convincing
evidence
susceptibility
infection
among
individuals
with
dysregulated
immune
response
comorbidities.
Herein,
we
provide
comprehensive
perspective
regarding
vulnerability
in
patients
underlying
medical
We
discuss
ongoing
vaccine
(mRNA,
protein-based,
viral
vector-based,
etc.)
therapeutic
(monoclonal
antibodies,
small
molecules,
plasma
therapy,
modalities
designed
curb
pandemic.
also
detail,
challenges
posed
different
(VOC)
identified
across
globe
their
effects
on
prophylactic
interventions.
ACS Applied Nano Materials,
Journal Year:
2021,
Volume and Issue:
4(12), P. 14014 - 14025
Published: Dec. 9, 2021
Using
surface-initiated
atom-transfer
radical
polymerization,
temperature-responsive
block
polymers
were
functionalized
on
the
surface
of
silica
nanocapsules
(SNCs)
by
a
"grafting-from"
technique.
Favipiravir,
potential
medicine
candidate
for
treatment
coronavirus
disease
(COVID-19),
was
encapsulated
in
polymer-coated
SNCs
and
further
incorporated
into
well-defined
films
layer-by-layer
self-assembly.
The
multilayer
composed
poly(methacrylic
acid)
(PMAA)
homopolymers
exhibited
swelling/deswelling
behaviors
under
trigger
temperature
stimulus.
For
first
time,
impact
steric
hindrance
assembling
behavior,
transition,
delivering
capacity
nanocapsule-based
investigated.
with
coronae
higher
resulted
larger
layering
distance
during
film
growth.
Moreover,
difference
sustained
release
rates
drug
indicated
their
diverse
diffusion
coefficients
intermolecular
interactions
within
films,
due
to
presence
methyl
spacer
at
amino
group
nanocapsule
weaker
ionic
pairing
between
SNC
PMAA
homopolymers.
profile
from
dependent
value
surrounding
environment.
At
37
40
°C,
able
efficiently
entrap
favipiravir,
as
low
50%
released
80
days,
whereas
faster
favipiravir
triggered
exposure
lower
25
°C.
This
work
demonstrates
proof-of-concept
platform
SNC-incorporated
multilayered
internal
structure
on-demand
vitro
delivery.
The Science of The Total Environment,
Journal Year:
2021,
Volume and Issue:
814, P. 152691 - 152691
Published: Dec. 30, 2021
During
the
COVID-19
pandemic,
high
consumption
of
antivirals,
antibiotics,
antiparasitics,
antiprotozoals,
and
glucocorticoids
used
in
treatment
this
virus
has
been
reported.
Conventional
systems
fail
to
efficiently
remove
these
contaminants
from
water,
becoming
an
emerging
concern
environmental
field.
Therefore,
objective
present
work
is
address
current
state
literature
on
presence
removal
processes
drugs
water
bodies.
It
was
found
that
concentration
most
increased
during
pandemic
Before
Azithromycin
concentrations
surface
waters
were
reported
be
order
4.3
ng
L
European journal of medical research,
Journal Year:
2022,
Volume and Issue:
27(1)
Published: Jan. 13, 2022
SARS-CoV-2,
a
novel
coronavirus,
is
the
agent
responsible
for
COVID-19
pandemic
and
major
public
health
concern
nowadays.
The
rapid
global
spread
of
this
coronavirus
leads
to
an
increase
in
hospitalizations
thousands
deaths
many
countries.
To
date,
great
efforts
have
been
made
worldwide
efficient
management
crisis,
but
there
still
no
effective
specific
treatment
COVID-19.
primary
therapies
treat
disease
are
antivirals,
anti-inflammatories
respiratory
therapy.
In
addition,
antibody
currently
active
essential
part
SARS-CoV-2
infection
treatment.
Ongoing
trials
proposed
different
therapeutic
options
including
various
drugs,
convalescent
plasma
therapy,
monoclonal
antibodies,
immunoglobulin
cell
present
study
summarized
current
evidence
these
approaches
assess
their
efficacy
safety
We
tried
provide
comprehensive
information
about
available
potential
against
support
researchers
physicians
any
future
progress
treating
patients.
Clinical Microbiology and Infection,
Journal Year:
2022,
Volume and Issue:
28(4), P. 602 - 608
Published: Jan. 11, 2022
To
evaluate
whether
favipiravir
reduces
the
time
to
viral
clearance
as
documented
by
negative
RT-PCR
results
for
severe
acute
respiratory
syndrome
coronavirus
2
in
mild
cases
of
disease
2019
(COVID-19)
compared
placebo.
Pharmacological Reports,
Journal Year:
2022,
Volume and Issue:
74(6), P. 1255 - 1278
Published: July 25, 2022
The
use
of
antiviral
COVID-19
medications
can
successfully
inhibit
SARS-CoV-2
replication
and
prevent
disease
progression
to
a
more
severe
form.
However,
the
timing
treatment
plays
crucial
role
in
this
regard.
Oral
drugs
provide
an
opportunity
manage
infection
without
need
for
hospital
admission,
easing
general
burden
that
have
on
healthcare
system.
This
review
paper
(i)
presents
potential
pharmaceutical
targets,
including
various
host-based
targets
viral-based
(ii)
characterizes
first-generation
anti-SARS-CoV-2
oral
(nirmatrelvir/ritonavir
molnupiravir),
(iii)
summarizes
clinical
progress
other
antivirals
COVID-19,
(iv)
discusses
ethical
issues
such
trials
(v)
challenges
associated
with
practice.
represent
part
strategy
adapt
long-term
co-existence
manner
prevents
from
being
overwhelmed.
It
is
pivotal
ensure
equal
fair
global
access
currently
available
those
authorized
future.
TURKISH JOURNAL OF MEDICAL SCIENCES,
Journal Year:
2021,
Volume and Issue:
51(SI-1), P. 3372 - 3390
Published: Aug. 15, 2021
Currently
there
is
not
an
effective
antiviral
treatment
for
COVID-19,
but
a
large
number
of
drugs
have
been
evaluated
since
the
beginning
pandemic,
and
many
them
used
COVID-19
despite
preliminary
or
conflicting
results
clinical
trials.
We
aimed
to
review
summarize
all
current
knowledge
on
antivirals
COVID-19There
are
2
main
drug
groups
SARS-CoV-2:
agents
that
target
proteins
RNA
virus
interfere
with
biological
processes
in
host
support
virus.
The
include
inhibitors
viral
entry
into
human
cell
(convalescent
plasma,
monoclonal
antibodies,
nanobodies,
mini
proteins,
soluble
ACE-2,
camostat,
dutasteride,
proxalutamide,
bromhexin,
hydroxychloroquine,
umifenovir
nitazoxanid,
niclosamide,
lactoferrin),
proteases
(lopinavir/ritonavir,
PF-07321332,
PF-07304814,
GC376),
(remdesivir,
favipiravir,
molnupiravir,
AT-527,
merimepodib,
PTC299),
supporting
(plitidepsin,
fluvoxamine,
ivermectin),
natural
immunity
(Interferons).When
taking
account
available
laboratory
trials
subject,
antibodies
seem
be
most
at
moment,
high-titer
convalescent
plasma
also
could
when
administered
during
early
phase
disease.
As
lopinavir/ritonavir,
were
found
ineffective
RCTs,
they
should
used.
Additional
studies
needed
define
role
remdesivir,
interferons,
ivermectin,
proxulutamide,
bromhexine,
nitazoxanide,
niclosamid
COVID-19.
Finally,
waited
learn
whether
newer
such
as
plitidepsin
AT-527
British Journal of Clinical Pharmacology,
Journal Year:
2021,
Volume and Issue:
88(5), P. 2065 - 2073
Published: Nov. 1, 2021
Aims
Fluvoxamine,
a
selective
serotonin
reuptake
inhibitor
(SSRI)
and
sigma‐1
receptor
agonist,
has
so
far
shown
promise
in
the
prevention
of
COVID‐19
progression
as
an
early
treatment
option
three
trials.
The
aim
this
study
was
to
evaluate
safety
efficacy
fluvoxamine
patients
if
administered
later
course
disease.
Methods
designed
open‐label,
prospective
cohort
trial
with
matched
controls.
In
April
May
2021,
51
ICU
hospitalised
University
Hospital
Dubrava
Centre
Zagreb,
Croatia,
were
treated
100
mg
times
daily
for
15
days
addition
standard
therapy
they
prospectively
age,
gender,
vaccination
against
COVID‐19,
disease
severity
comorbidities
Results
No
statistically
significant
differences
between
groups
observed
regarding
number
on
ventilator
support,
duration
or
total
hospital
stay.
However,
overall
mortality
lower
group,
58.8%
(
n
=
30/51),
than
control
76.5%
39/51),
HR
0.58,
95%
CI
(0.36–0.94,
P
.027).
Conclusion
Fluvoxamine
could
have
positive
impact
patient
survival.
Further
studies
effects
are
urgently
required.
